SCHEMBL1850149

SCHEMBL1850149

NC(=O)c1cccc(-c2c(F)ccc3cc(Cc4cccc(C(F)(F)F)c4)sc23)c1

nearest known ligand 0.59

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 18/20 0.59
ADORA2A P29274 1/20 0.42
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1847806 0.91 GPR52 (0.56) GPR52ADORA2A
SCHEMBL1846847 0.89 GPR52 (0.77) GPR52
SCHEMBL3211107 0.87 GPR52 (0.54) GPR52
SCHEMBL1852567 0.85 GPR52 (0.78) GPR52ADORA2A
SCHEMBL1851958 0.84 GPR52 (0.51) GPR52
SCHEMBL3198227 0.83 GPR52 (0.79) GPR52ADORA2AMAOB
SCHEMBL1850540 0.83 GPR52 (0.78) GPR52
SCHEMBL3223178 0.82 GPR52 (0.60) GPR52MAOB
SCHEMBL1850572 0.80 GPR52 (0.74) GPR52ADORA2AMAOB
SCHEMBL1853546 0.80 GPR52 (0.65) GPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323978-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-05-25 EP disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885ADORA2A 212/4885MAOB 1106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.